CDH5

Across TCGA pan-cancer cohorts, CDH5 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CDH5 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher CDH5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CDH5 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

READ, LIHC, and UCEC are the cancer types where CDH5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	DFS	Median	All	0.128	0.824	<.001	24	view →
LIHC	DFS	Median	All	0.060	0.544	<.001	24	view →
UCEC	DFS	Median	All	1.000	0.602	.001	20	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	12	view →
CHOL	OS	Median	All	0.154	0.793	.004	9	view →
LGG	DFS	Median	All	0.110	0.826	<.001	3	view →
SKCM	DFS	Median	All	0.804	0.610	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CDH5–READ (DFS)

Open the READ breakdown →